5.6 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) in patients treated with liraglutide injection [see Adverse Reactions (6.2)]
Examples of these drugs include: sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as: canagliflozin (Invokana) empagliflozin (Jardiance) ertugliflozin (Steglatro) incretin mimetics/glucagon-like peptide-1 (GLP1) receptor agonists, such as: metformin (Glumetza), which is a biguanide dipeptidyl peptidase-4 (DPP-4) inhibitors, such as: alogliptin (Nesina) linagliptin (Tradjenta) saxagliptin (Onglyza) sitagliptin (Januvia) thiazolidinediones, such as: alpha-glucosidase inhibitors, such as: miglitol sulfonylureas, such as: glimepiride (Amaryl) glipizide (Glucotrol) glyburide (Glynase, Diabeta) Alternatives for heart failure Examples of other drugs that may be used to reduce the risk of certain complications in people with heart failure include: angiotensin converting enzyme (ACE) inhibitors, such as: captopril enalapril (Vasotec) lisinopril (Zestril) angiotensin II receptor blockers (ARBs), such as: losartan (Cozaar) candesartan (Atacand) valsartan (Diovan) angiotensin receptor neprilysin inhibitors (ARNI), such as sacubitril/valsartan (Entresto) beta-blockers, such as: bisoprolol carvedilol (Coreg) metoprolol (Toprol XL) mineralocorticoid receptor antagonists, such as spironolactone (Aldactone) Alternatives for kidney disease Examples of other drugs that may be used to reduce the risk of certain complications in people with chronic (long-lasting) kidney disease include: phosphate binders, such as: calcium acetate (PhosLo) lanthanum carbonate (Fosrenol) sevelamer hydrochloride (Renagel) sucroferric oxyhydroxide (Velphoro) vitamin D analogs, such as calcitriol (Rocaltrol) doxercalciferol (Hectorol) paricalcitol (Zemplar) iron supplements, such as: ferrous sulfate iron sucrose (Venofer) iron dextran (Dexferrum) ferric gluconate (Ferrlecit) ferric carboxymaltose (Injectafer) the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (Invokana), which should not be used with Farxiga finerenone (Kerendia) Farxiga and Jardiance (empagliflozin) are both in the same class of medications: sodium-glucose co-transporter 2 (SGLT2) inhibitors
Severe weakness, a very fast heartbeat, and anxiety can also happen
Understanding potential risks helps patients work with their healthcare provider to choose best option
And certainly, a medication that has already been approved for use in humans is a huge time saver and one of the reasons we looked at these existing medications
